Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

• Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich’s ataxia (FA) anticipated in 2H 2025 following recent FDA IND clearance - - CPVT: Submission of IND for SGT-501 on track for 1H 2025; the submission will expand clinical-stage portfolio to three unique candidates in div ...